ArticleBreast cancer (Dove Medical Press)2026
Combined Treatment with Shuyu Pills and Everolimus Suppresses Triple-Negative Breast Cancer Growth via the PI3K/AKT/mTOR Pathway.
Article in Breast cancer (Dove Medical Press), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Triple-negative breast cancer (TNBC) is clinically characterized by the absence of therapeutic targets and limited treatment options after surgery, leading to poor therapeutic outcomes and prognosis. Shuyu Pills (SYP), a classical traditional Chinese medicine (TCM) formula for treating deficiency syndromes with pathogenic excess, has been widely applied in the treatment of TNBC. However, its mechanisms of action against TNBC remain unclear. Purpose: This study aimed to investigate the anti-tumor effect and the underlying mechanisms of SYP in combination with the mTOR inhibitor everolimus in TNBC both in vitro and in vivo experiments. Methods: Network pharmacology was used to predict the potential signaling pathways targeted by SYP. The pharmacological effects of SYP and its combination with everolimus were evaluated through in vitro and in Results: The combination of SYP and everolimus exhibits synergistic effects in inhibiting TNBC. Synergistic therapy suppressed TNBC cell proliferation and colony formation, cell migration and invasion, induced cell cycle arrest and apoptosis and reduced tumor growth in TNBC-bearing mice. The addition of SYP significantly promoted apoptosis of TNBC cells via regulated apoptosis-related protein including Bax, Caspase3, Bcl-2, CDK1 and Cyclin B. Further, synergistic treatment reduced TNBC tumor growth and Ki67 expression. Furthermore, the combined therapy effectively suppresses the expression of PI3K, p-PI3K, AKT, p-AKT, mTOR, and p-mTOR proteins. Conclusion: The present study aimed to investigate the pharmacological mechanism of the SYP. SYP can inhibit the proliferation, migration, and invasion of TNBC cells by arresting the cell cycle and inducing apoptosis. This mechanism may involve downregulation of the PI3K/AKT/mTOR signaling pathway. SYP can cooperate with everolimus to inhibit TNBC. Overall, these findings provide valuable evidence for the potential clinical application of SYP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.